MMMaria Gabriela Morales

Maria Gabriela Morales

*This is an algorithmically generated author record based on publicly available information.

Maria Gabriela Morales has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retinal BMI1 Expression Preserves Photoreceptors in Sodium-Iodate-Induced Oxidative Stress Models

    by Zhongyang Lu, Shufeng Liu, Maria G. Morales, Andy Whitlock, Ram Ramkumar, Hema L. Ramkumar

    Dry age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 50, yet no approved therapies exist for early or intermediate stages of the disease. Oxidative stress is a central driver of retinal degeneration in AMD, and sodium iodate (NaIO3)-induced injury serves as a well-characterized model of oxidative damage to the retinal pigment epithelium (RPE) and photoreceptors. BMI1, a poly-comb group protein involved in DNA repair, mitochondrial function, and cellular renewal, has emerged as a promising therapeutic target for retinal neuroprotection. We evaluated the efficacy of AAV-mediated BMI1 gene delivery in murine models using two administration routes: subretinal (SR) and suprachoroidal (SC). AAV5.BMI1 (1 × 109 vg/eye) was delivered SR in Balb/c mice and evaluated at 4 and 15 weeks post-injection. AAV8.BMI1 (5 × 109 or 1 × 1010 vg/eye) was administered SC in C57BL/6 mice and assessed at 4 weeks. Control groups received BSS or AAV8.stuffer. Following NaIO3 exposure, retinal structure and function were analyzed by optical coherence tomography (OCT), electroretinography (ERG), histology, and molecular assays. SC delivery of AAV8.BMI1 achieved the highest levels of retinal BMI1 expression with no evidence of local or systemic toxicity. Treated eyes showed dose-dependent preservation of outer nuclear layer (ONL) thickness and significantly improved ERG responses indicating structural and functional protection. These findings support SC AAV.BMI1 gene therapy as a promising, minimally invasive, and translatable approach for early intervention in intermediate AMD.


  • Open Access

    Retinal BMI1 Expression Preserves Photoreceptors in Sodium Iodate-Induced Oxidative Stress Models

    by Zhongyang Lu, Shufeng Liu, Maria Gabriela Morales, Andy Whitlock, Ram Ramkumar, Hema Ramkumar

    Dry age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 with limited therapeutic options. The sodium iodate (NaIO3)-induced retinal degeneration model mimics oxidative stress-induced cell death in dry AMD. BMI1, a polycomb ring finger protein involved in DNA repair and cell renewal, is a potential therapeutic target for oxidative retinal injury. We evaluated the efficacy of AAV-mediated BMI1 gene delivery in Balb/c and C57BL/6 mice using two routes: subretinal (SR) and suprachoroidal (SC). AAV5.BMI1 (1×10⁹ vg/eye) was delivered SR in Balb/c mice, and efficacy was assessed after 4 and 15 weeks. AAV8.BMI1 (5×10⁹ or 1×10¹⁰ vg/eye) was administered SC in C57BL/6 mice, with evaluation after 4 weeks. Control groups received BSS or AAV8.stuffer. Following NaIO₃ administration, retinal function and structure were analyzed by optical coherence tomography (OCT), electroretinography (ERG), histology, and tissue assays. SC delivery of AAV8.BMI1 achieved the highest transduction and BMI1 expression without adverse effects, leading to dose-dependent ONL preservation and improved ERG responses. These findings suggest that SC AAV-mediated BMI1 gene delivery effectively enhances retinal health and function and prevents retinal degeneration, supporting its use as a promising therapeutic approach for intermediate AMD to prevent advanced disease.


  • Open Access

    Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy

    by Patrizia Pessina, Daniel Cabrera, María Gabriela Morales, Cecilia A Riquelme, Jaime Gutiérrez, Antonio L Serrano, Enrique Brandan, Pura Muñoz-Cánoves

    Fibrosis, an excessive collagen accumulation, results in scar formation, impairing function of vital organs and tissues. Fibrosis is a hallmark of muscular dystrophies, including the lethal Duchenne muscular dystrophy (DMD), which remains incurable. Substitution of muscle by fibrotic tissue also complicates gene/cell therapies for DMD. Yet, no optimal models to study muscle fibrosis are available. In the widely used mdx mouse model for DMD, extensive fibrosis develops in the diaphragm only at advanced adulthood, and at about two years of age in the ‘easy-to-access’ limb muscles, thus precluding fibrosis research and the testing of novel therapies.


  • Open Access

    Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis

    by Daniel Cabrera, Jaime Gutiérrez, Claudio Cabello-Verrugio, Maria Gabriela Morales, Sergio Mezzano, Ricardo Fadic, Juan Carlos Casar, Juan L Hancke, Enrique Brandan

    Duchenne muscular dystrophy (DMD) is characterized by the absence of the cytoskeletal protein dystrophin, muscle wasting, increased transforming growth factor type beta (TGF-β) signaling, and fibrosis. At the present time, the only clinically validated treatments for DMD are glucocorticoids. These drugs prolong muscle strength and ambulation of patients for a short term only and have severe adverse effects. Andrographolide, a bicyclic diterpenoid lactone, has traditionally been used for the treatment of colds, fever, laryngitis, and other infections with no or minimal side effects. We determined whether andrographolide treatment of mdx mice, an animal model for DMD, affects muscle damage, physiology, fibrosis, and efficiency of cell therapy.